Special Issue

State-of-the-Art Neurobiology and Clinical Neuroscience in the United States

Message from the Guest Editors

Recent advances in neurobiology and clinical neuroscience show population-specific differences in neuropathology and genetic risk for various neurodegenerative diseases. This Special Issue is part of a series of Special Issues specific to different regions of the world and is intended to help researchers better understand the current state of clinical neuroscience in their region, in this case the United States. Areas of special interest include, but are not limited to, the following:

- General neurobiology;
- Advances in classifying specific neurodegenerative diseases;
- Novel techniques for measuring changes in neurobiology;
- Clinical applications of neuroscience;
- Interesting case studies;
- Advances in artificial intelligence and machine learning related to neurobiology or neuroscience;
- Comparative studies of neurobiology between the United States and other regions.

We invite you to reach out to and Laura Ibanez if you have any questions related to this Special Issue.

Guest Editors

Dr. Justin Miller

1. Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY 40536, USA
2. Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40536, USA
3. Division of Biomedical Informatics, Department of Internal Medicine, University of Kentucky, Lexington, KY 40536, USA
4. Department of Microbiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, KY 40536, USA

Dr. Laura Ibanez

1. Department of Psychiatry, Washington University in Saint Louis School of Medicine, 4444 Forest Park, Campus Box 8134, Saint Louis, MO 63110, USA
2. NeuroGenomics and Informatics Center, Washington University in Saint Louis School of Medicine, Saint Louis, MO 63110, USA
3. Department of Neurology, Washington University in Saint Louis School of Medicine, Saint Louis, MO 63110, USA

Deadline for manuscript submissions

Biomedicines

**an Open Access Journal
by MDPI**

**Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed**

mdpi.com/journal/
biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).